Ken Griffin Vanda Pharmaceuticals Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$4.61 - $6.34 $199,152 - $273,888	-43,200 Reduced 67.19%	21,100 $98,000
Q2 2024 Aug 14, 2024	BUY	$3.91 - $6.5 $95,795 - $159,250	24,500 Added 61.56%	64,300 $363,000
Q1 2024 May 15, 2024	BUY	$3.47 - $4.61 $70,094 - $93,122	20,200 Added 103.06%	39,800 $163,000
Q4 2023 Feb 14, 2024	BUY	$3.38 - $4.58 $54,418 - $73,738	16,100 Added 460.0%	19,600 $82,000
Q3 2023 Nov 14, 2023	SELL	$4.28 - $6.57 $2,996 - $4,599	-700 Reduced 16.67%	3,500 $15,000
Q2 2023 Aug 14, 2023	BUY	$5.9 - $6.95 $10,030 - $11,815	1,700 Added 68.0%	4,200 $27,000
Q1 2023 May 15, 2023	SELL	$6.18 - $7.99 $90,228 - $116,654	-14,600 Reduced 85.38%	2,500 $16,000
Q4 2022 Feb 14, 2023	BUY	$6.87 - $10.96 $117,477 - $187,416	17,100 New	17,100 $126,000

159

44.9M

165K

33.6K

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $251M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.